Navigation Links
3-V Biosciences Completes $20 Million Series C Financing

MENLO PARK, Calif., June 21, 2013 /PRNewswire/ -- 3-V Biosciences, Inc., a biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious disease, today announced the completion of a Series C financing round, raising $20 million. Proceeds from the financing will be used to advance 3-V's lead oncology candidate into a Phase 1 clinical trial and to conduct ongoing preclinical studies of multiple virology leads generated by the company's integrated drug discovery process. Existing investors Kleiner Perkins Caufield & Byers and New Enterprise Associates participated in the round.


"I am very pleased by the recognition of our efforts and continued support from our existing investors," said Merdad Parsey, M.D., Ph.D., Chief Executive Officer of 3-V Biosciences. "3-V takes an integrated approach to building its pipeline by applying our proprietary screening methodology combined with our expertise in medicinal chemistry, drug discovery and development to generate proprietary therapeutic candidates that target key pathways in oncology and infectious diseases. Our lead oncology candidate has demonstrated compelling anti-tumor activity in pre-IND studies and with the funds from our Series C, we look forward to advancing into the clinic later this year."

3-V's lead molecule is one of a series of novel fatty acid synthase (FASN) inhibitors initially being developed to treat solid tumor cancers. FASN over-expression is associated with aggressive disease and poor prognosis in a number of cancers. In a series of preclinical studies, 3-V has demonstrated potent activity against multiple tumor types, including lung, breast, prostate and colon cancers. In addition, 3-V has demonstrated potential synergy of its FASN-inhibitors with cytotoxic agents. 3-V plans to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in the third quarter and initiate first-in-human studies by the end of 2013.

"The team at 3-V has done an impressive job of generating a pipeline of novel therapeutic product candidates with promising activity in diverse oncology and infectious disease indications," said David Mott, General Partner of New Enterprise Associates and Chairman of the Board of 3-V Biosciences. "We are pleased to support 3-V's continued efforts as they advance their lead program into clinical development."

3-V is leveraging its screening platform, drug discovery and drug development capabilities to identify antiviral candidates that exploit the dependence of the virus on the host cell by blocking host-virus interactions. The leads in the company's pipeline are characterized by their novel mechanism of action, broad-spectrum antiviral activity and high barrier to resistance. 3-V is currently evaluating antiviral therapeutic candidates for respiratory syncytial virus (RSV), herpes simplex virus (HSV) and hepatitis C virus (HCV).

About 3-V Biosciences
3-V Biosciences, Inc. is a privately held biopharmaceutical company discovering and developing therapeutics that modulate key pathways in oncology and infectious disease. In oncology, the company's lead candidate is a fatty acid synthase (FASN) inhibitor that blocks tumor cell signaling pathways and induces tumor cell apoptosis. 3-V's antiviral therapeutics block host-pathogen interactions, resulting in robust and broad-spectrum antiviral activity, including efficacy against viruses resistant to other classes of antiviral drugs, and a high barrier to resistance. The 3-V team applies an integrated approach, leveraging internal expertise in biology, medicinal chemistry, drug discovery and development to drive programs forward. The company is located in Menlo Park, California.

For additional information on 3-V Biosciences, please visit

Contact information

Merdad Parsey, M.D., Ph.D.
Chief Executive Officer

Media Inquiries

BCC Partners on behalf of 3-V Biosciences, Inc.
Karen L. Bergman
Michelle Corral

SOURCE 3-V Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
3. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
4. Neurocrine Biosciences Reports First Quarter 2012 Results
5. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
8. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
9. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
10. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
11. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  ARKRAY USA ... continues to provide evidence demonstrating the accuracy of its ... Congress on Insulin Resistance, Diabetes and Cardiovascular Disease in ... both the Company,s GLUCOCARD ® 01 meter and ... accuracy requirements. The ability to accurately measure glucose levels ...
(Date:11/25/2015)... 2015  Trovagene, Inc. (NASDAQ: TROV ), a ... Executive Officer Antonius Schuh, Ph.D., is scheduled to present ... Piper Jaffray Healthcare Conference. th Annual ... Hotel in New York on ... Schuh will be available for one-on-one meetings during the ...
(Date:11/25/2015)... , Nov. 25, 2015 USP ... hazardous drug preparations (e.g. pharmacists, pharmacy technicians, nurses, ... veterinary technicians). The chapter also covers all entities ... (e.g., pharmacies, hospitals, other healthcare institutions, patient treatment ... --> --> What ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Brillianteen, ... friendships, and learning in its 65th Anniversary Brillianteen Revue, scheduled for March 4-6, ... , For 65 years, Brillianteen has been a treasured tradition for numerous families ...
(Date:11/25/2015)... ... November 25, 2015 , ... Castlewood Treatment Center for Eating ... disorders as a result of the $20,000 raised at the center’s recent ... Golf Club in Eureka, will help individuals who otherwise might not seek treatment ...
(Date:11/25/2015)... ... November 25, 2015 , ... An unlikely ... resulting in a way for homeless people to have a more dignified and ... new initiative whereby they are repurposing plastic bags into sleeping mats for the ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something to be thankful ... Create Real Impact awards. California Casualty is proud to support the contest ... distracted and reckless driving, the number one killer of young drivers. , Almost ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Dr. Todd S. ... offer laser services to many of his patients. Dr. Afferica now uses the BIOLASE ... reduce the amount of time the doctor uses other traditional cutting tools, such as ...
Breaking Medicine News(10 mins):